Inavac Manufacturer Asks Government To Facilitate Remaining Opportunity To Work On Booster Vaccination

Director of PT Biotis Pharmaceuticals Indonesia FX Sudirman showing the Inavac Vaccine in the quality inspection room, Wednesday (7/9/2022). (ANTARA/Andi Firdaus).

JAKARTA - PT Biotis Pharmaceuticals Indonesia as a private producer of Inavac Vaccines in Bogor Regency, West Java, asked the government to provide market opportunities from the remaining coverage of the COVID-19 vaccination booster or booster doses.

"Most of the Indonesian people need booster vaccinations. Currently, there are still 98.7 million people who have not received booster vaccines," said Director of PT Biotis Pharmaceuticals Indonesia FX Sudirman during a media visit to the Inavac Vaccine Production Plant in Gunung Sindur, Bogor Regency, West Java, as reported by ANTARA, Wednesday, September 7th.

PT Biotis as the producer of the Red and White Vaccine by the Airlangga University Research Team with the Inavac trademark is eyeing market opportunities from booster vaccination coverage for adults, adolescents, and children.

To date, booster vaccinations for those aged over 18 have only covered 30 percent of the target of 141,211,000 people, so there are still 98.7 million people who have not had the booster vaccine.

Meanwhile, booster vaccination for adolescents aged 12-17 years with a target number of 26,705,490 has not yet started in Indonesia.

The booster vaccination for children aged 7-11 years with a target number of 26,400,300 has not yet started.

"That's what we ask the government. If in October, November, December 2022 the vaccine can be released, we hope the Inavac vaccine can be used for adult booster vaccines. I think the end of the year is already underway," he said.

The Inavac vaccine with the Inactivated Virus platform has so far entered the interim phase 3 report. It is targeted that by September 2022 Inavac will obtain an emergency marketing permit (EUA) from the Food and Drug Administration (BPOM).

Sudirman said the mass production process has been rolling since June 12, 2022, and the release of vaccine products is expected to start September 28, 2022.

"In line with phase 3 clinical trials (primary vaccines), a booster vaccine clinical trial for adults was conducted in parallel after obtaining approval for clinical trials since August 28. We hope that they will be completed together," he said.

The policy of parallel clinical trials, said Sudirman, is to pursue the target of achieving booster vaccination coverage, which is still remaining in the country.